Hemophilia: Bispecific Antibody

Here is an editorial that appeared in the December, 2016 Journal of Thrombosis and Haemostasis describing the thinking that led to a coagulation factor VIII mimetic. This is a bispecific antibody that approximates factors IX and X to activate X while bypassing factor VIII. Designated ACE910, the mimetic enables normal clotting in hemophilia A when an inhibitor is present. Editors Rosendaal and Reitsma give the pros and cons of ACE910.

Rosendaal FR, Reitsma PH. Out of the box. J Thromb Haemost 2016; 14: 2323.